




# Adrenal Hormone Report; saliva

**Order:** SAMPLE REPORT**Client #:** 12345**Doctor:** Sample Doctor, MD  
Doctors Data Inc.  
3755 Illinois Ave.  
St. Charles, IL 60174**Patient:** Sample Report**Age:** 57**Sex:** Female**Body Mass Index (BMI):** N/A**Menopausal Status:** Post-Menopausal**Sample Collection Date/Time**

<b>Date Collected</b>	10/01/2018
<b>AM30</b>	10/01/2018 0800
<b>Noon</b>	10/01/2018 1200
<b>Evening</b>	10/01/2018 1700
<b>Night</b>	10/01/2018 2100
<b>Date Received</b>	10/03/2018
<b>Date Reported</b>	10/05/2018

Analyte	Result	Unit	L	WRI	H	Optimal Range	Reference Interval
<b>Cortisol AM30</b>	11	nmol/L	◆			14.0 - 25.0	5.1 - 30.0
<b>Cortisol Noon</b>	4.7	nmol/L	◆			5.0 - 10.0	2.1 - 14.0
<b>Cortisol Evening</b>	2.5	nmol/L		◆		2.0 - 5.0	1.5 - 8.0
<b>Cortisol Night</b>	0.80	nmol/L	◆			1.0 - 4.0	0.33 - 7.0
<b>DHEA*</b>	181	pg/mL		◆			106 - 300

**Cortisol Graph****Hormone Comments:**

- The suboptimal diurnal cortisol pattern and reported symptoms are consistent with evolving (Phase 2) HPA axis (adrenal gland) dysfunction.

**Adrenal Phase: 2****Notes:**

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI)  
The current samples are routinely held three weeks from receipt for additional testing.

\*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Methodology: Enzyme Immunoassay



# Hormone Report; saliva

**Order:** SAMPLE REPORT**Client #:** 12345**Doctor:** Sample Doctor, MD  
Doctors Data Inc.  
3755 Illinois Ave.  
St. Charles, IL 60174**Patient:** Sample Report**Age:** 57**Sex:** Female**Body Mass Index (BMI):** N/A**Menopausal Status:** Post-Menopausal**Sample Collection** **Date/Time****Date Collected** 10/01/2018  
**AM30** 10/01/2018 0800  
**Noon** 10/01/2018 1200  
**Evening** 10/01/2018 1700  
**Night** 10/01/2018 2100  
**Date Received** 10/03/2018  
**Date Reported** 10/05/2018

Analyte	Result	Unit	L	WRI	H	Reference Interval	Supplementation Range**
Estradiol (E2)	0.85	pg/mL		◆		0.5 - 3.2	1.5 - 7.2
Progesterone (Pg)	27	pg/mL		◆		18 - 126	500 - 3000
Pg/E2 Ratio	31.8		↓			200 - 600	
Testosterone	82	pg/mL			↑	6.0 - 49	30 - 60
DHEA*	181	pg/mL		◆		106 - 300	

**Hormone Comments:**

- Suboptimal estradiol is consistent with the reported deficiency symptoms. Progesterone to estradiol (Pg/E2) ratio and reported symptoms are consistent with progesterone insufficiency (estrogen dominance). Supplementation with topical progesterone to correct this relative deficiency is a consideration.
- The elevated testosterone is suggestive of metabolic syndrome (insulin resistance), although exogenous exposure (not reported) cannot be excluded. Serum vitamin D, hemoglobin A1c and insulin testing may be warranted.

**Notes:**

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI)  
The current samples are routinely held three weeks from receipt for additional testing.

The Pg/E2 ratio is an optimal range established based on clinical observation. Progesterone supplementation is generally required to achieve this level in men and postmenopausal women.

\*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

\*\*If supplementation is reported then the supplementation ranges will be graphed. The supplementation ranges depicted are for informational purposes only and were derived from a cohort of adult men and women utilizing physiologic transdermal bioidentical hormone therapy.

Methodology: Enzyme Immunoassay